Literature has also reported that the MDM2 binding protein (MTBP) interacts with the PXR and accumulates PXR in the nucleus, thereby facilitating PXR-CYP3A4 transactivation, which leads to the resistance of HCC cells to sorafenib. The gene discussed is CYP3A4; the disease is hepatocellular carcinoma.